{"id":52152,"date":"2025-12-29T13:03:06","date_gmt":"2025-12-29T05:03:06","guid":{"rendered":"https:\/\/flcube.com\/?p=52152"},"modified":"2025-12-29T13:03:06","modified_gmt":"2025-12-29T05:03:06","slug":"astrazeneca-and-ionis-eplontersen-wins-china-approval-for-attrv-pn-as-first-gene-silencing-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52152","title":{"rendered":"AstraZeneca and Ionis&#8217; Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy"},"content":{"rendered":"\n<p><strong>AstraZeneca PLC<\/strong> (AZ, <a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NASDAQ\">NASDAQ:\u202fAZN<\/a>) and <strong>Ionis Pharmaceuticals<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/IONS:NASDAQ\">NASDAQ:\u202fIONS<\/a>) announced that <strong>Wainua (eplontersen)<\/strong> has received approval from <strong>China\u2019s National Medical Products Administration (NMPA)<\/strong> for the treatment of adult patients with <strong>hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN)<\/strong>, marking the <strong>first and only gene-silencing agent<\/strong> cleared for this indication in China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Wainua (eplontersen)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>RNA-targeted gene-silencing agent (antisense oligonucleotide)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Hereditary transthyretin-mediated amyloidosis in adults (ATTRv-PN)<\/td><\/tr><tr><td><strong>Regulator<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>25\u202fDec\u202f2025<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td><strong>First approved gene-silencing therapy<\/strong> for ATTRv-PN in China; self-administered monthly via auto-injector<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-profile-amp-unmet-need\">Disease Profile &amp; Unmet Need<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: ~30,000-50,000 affected individuals in China; diagnosis rate &lt;5%<\/li>\n\n\n\n<li><strong>Clinical Course<\/strong>: Motor dysfunction within 5\u202fyears post-diagnosis; median survival &lt;10\u202fyears without disease-modifying treatment<\/li>\n\n\n\n<li><strong>Economic Burden<\/strong>: Annual direct healthcare costs \u00a5200,000-300,000 per patient; indirect disability costs exceed \u00a5400,000<\/li>\n\n\n\n<li><strong>Current Landscape<\/strong>: No approved disease-modifying therapies; limited to symptomatic management and liver transplant in select cases<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-neuro-ttransform-phase-3\">Clinical Evidence \u2013 NEURO\u2011TTRansform Phase\u202f3<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Eplontersen (66\u202fweeks)<\/th><th>External Placebo<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Co\u2011Primary: Serum TTR Concentration<\/strong><\/td><td>&gt;80% sustained reduction<\/td><td>Minimal change<\/td><td>Direct target engagement<\/td><\/tr><tr><td><strong>Co\u2011Primary: Neuropathy (mNIS+7)<\/strong><\/td><td>Stable vs. baseline<\/td><td>Progressive deterioration<\/td><td>Halts disease progression<\/td><\/tr><tr><td><strong>Key Secondary: QoL (Norfolk QoL\u2011DN)<\/strong><\/td><td>Sustained improvement<\/td><td>Declining scores<\/td><td>Patient\u2011reported benefit<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Well\u2011tolerated; 4% discontinuation due to AEs<\/td><td>\u2013<\/td><td>Favorable long\u2011term safety<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><em>Study Design: Randomized, controlled Phase\u202f3 trial; 66\u2011week observation period vs. external placebo comparator.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-strategic-position\">Drug Profile &amp; Strategic Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Targets transthyretin (TTR) mRNA; upstream inhibition of pathogenic protein production<\/li>\n\n\n\n<li><strong>Administration<\/strong>: Self\u2011administered monthly subcutaneous injection via auto\u2011injector; enables home treatment<\/li>\n\n\n\n<li><strong>Global Rollout<\/strong>: Approved US (FDA\u202fDec\u202f2023), EU (Mar\u202f2024); China approval completes major market entry<\/li>\n\n\n\n<li><strong>IP &amp; Partnership<\/strong>: Licensed from Ionis; AstraZeneca holds full commercial rights in Asia; co\u2011promotion strategy leverages AZ\u2019s rare disease infrastructure<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-financial-outlook\">Market Opportunity &amp; Financial Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Diagnosed ATTRv\u2011PN patients in China<\/strong><\/td><td>2,500<\/td><td>4,500<\/td><\/tr><tr><td><strong>Eplontersen\u2011eligible population<\/strong><\/td><td>2,000<\/td><td>3,600<\/td><\/tr><tr><td><strong>Peak market penetration<\/strong><\/td><td>35%<\/td><td>55%<\/td><\/tr><tr><td><strong>Annual treatment cost (\u00a5)<\/strong><\/td><td>380,000<\/td><td>320,000 (post\u2011NRDL)<\/td><\/tr><tr><td><strong>Estimated China revenue<\/strong><\/td><td>\u00a5266\u202fmillion<\/td><td>\u00a5633\u202fmillion (US$37\u201188\u202fmillion)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Launch Timeline<\/strong>: Q1\u202f2026 commercial rollout via specialty pharmacy channels<\/li>\n\n\n\n<li><strong>Reimbursement Strategy<\/strong>: Targeting 2026 NRDL negotiation; orphan drug designation supports premium pricing<\/li>\n\n\n\n<li><strong>Patient Support<\/strong>: \u201cWainua Care\u201d program launching Q1\u202f2026 with co\u2011pay assistance and genetic counseling services<\/li>\n\n\n\n<li><strong>Diagnostic Push<\/strong>: Partnering with <strong>BGI Genomics<\/strong> to expand TTR gene testing capacity and accelerate diagnosis<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><\/p>\n\n\n\n<p>This brief contains forward\u2011looking projections regarding eplontersen\u2019s market penetration, revenue potential, and reimbursement timelines in China. Actual results may differ materially due to competitive responses, diagnostic infrastructure limitations, and NRDL negotiation outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca PLC (AZ, NASDAQ:\u202fAZN) and Ionis Pharmaceuticals (NASDAQ:\u202fIONS) announced that Wainua (eplontersen) has received approval&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[130,1498,871,1497,15,24],"class_list":["post-52152","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-astrazeneca","tag-ionis-pharmaceuticals","tag-nasdaq-azn","tag-nasdaq-ions","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca and Ionis&#039; Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca PLC (AZ, NASDAQ:\u202fAZN) and Ionis Pharmaceuticals (NASDAQ:\u202fIONS) announced that Wainua (eplontersen) has received approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of adult patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN), marking the first and only gene-silencing agent cleared for this indication in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52152\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca and Ionis&#039; Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca PLC (AZ, NASDAQ:\u202fAZN) and Ionis Pharmaceuticals (NASDAQ:\u202fIONS) announced that Wainua (eplontersen) has received approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of adult patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN), marking the first and only gene-silencing agent cleared for this indication in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52152\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-29T05:03:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52152#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52152\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca and Ionis&#8217; Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy\",\"datePublished\":\"2025-12-29T05:03:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52152\"},\"wordCount\":422,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"Ionis Pharmaceuticals\",\"NASDAQ: AZN\",\"NASDAQ: IONS\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52152#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52152\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52152\",\"name\":\"AstraZeneca and Ionis' Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2025-12-29T05:03:06+00:00\",\"description\":\"AstraZeneca PLC (AZ, NASDAQ:\u202fAZN) and Ionis Pharmaceuticals (NASDAQ:\u202fIONS) announced that Wainua (eplontersen) has received approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of adult patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN), marking the first and only gene-silencing agent cleared for this indication in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52152#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52152\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52152#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca and Ionis&#8217; Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca and Ionis' Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca PLC (AZ, NASDAQ:\u202fAZN) and Ionis Pharmaceuticals (NASDAQ:\u202fIONS) announced that Wainua (eplontersen) has received approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of adult patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN), marking the first and only gene-silencing agent cleared for this indication in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52152","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca and Ionis' Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy","og_description":"AstraZeneca PLC (AZ, NASDAQ:\u202fAZN) and Ionis Pharmaceuticals (NASDAQ:\u202fIONS) announced that Wainua (eplontersen) has received approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of adult patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN), marking the first and only gene-silencing agent cleared for this indication in China.","og_url":"https:\/\/flcube.com\/?p=52152","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-29T05:03:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52152#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52152"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca and Ionis&#8217; Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy","datePublished":"2025-12-29T05:03:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52152"},"wordCount":422,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","Ionis Pharmaceuticals","NASDAQ: AZN","NASDAQ: IONS","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52152#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52152","url":"https:\/\/flcube.com\/?p=52152","name":"AstraZeneca and Ionis' Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2025-12-29T05:03:06+00:00","description":"AstraZeneca PLC (AZ, NASDAQ:\u202fAZN) and Ionis Pharmaceuticals (NASDAQ:\u202fIONS) announced that Wainua (eplontersen) has received approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of adult patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN), marking the first and only gene-silencing agent cleared for this indication in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52152#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52152"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52152#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca and Ionis&#8217; Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52152"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52152\/revisions"}],"predecessor-version":[{"id":52153,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52152\/revisions\/52153"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}